ADNI is one of the most important research studies in Alzheimer’s disease. More than 4,000 discoveries can be connected to ADNI since it began in 2004. ADNI participants continue to make huge contributions to science every year. Recently, ADNI data has been used for:
- An FDA-approved test for the early detection of amyloid plaques in the brain, a potential precursor to Alzheimer’s disease. The test uses spinal fluid, which could remove the need for PET scans. Not using PET scans can save time and money.
- A research breakthrough about APOE, a genetic marker that is a risk factor for Alzheimer’s. It was found that APOE has a relationship to late-onset Alzheimer's. This discovery could lead to new ideas for treatments.
- Artificial Intelligence (AI) technology that can predict if someone will eventually have Alzheimer's disease. The technology was correct 88% of the time for North American patients and 84% of the time for Japanese patients in a study.
ADNI is putting in effort to make sure diverse groups of people are included in research. This cycle, ADNI4, is focused on reflecting everyone. Over time, we have added more participants in our study from groups who are not often served equally in research. This includes Black, Latino/Hispanic, Asian, Pacific Islander/Native Hawaiian, and American Indian/Alaska Native participants.
In the past, less than 17% of ADNI participants were from groups underrepresented in clinical trials. Recent efforts by the study team have worked to include more diversity in our research. At the start of ADNI4, more than 22% of ADNI participants were from underrepresented groups. While we intend to keep leading the way, we know there is much more work to be done.
Each visit you complete adds to this incredible progress and makes a difference in Alzheimer's research.
Click here to read more about the ADNI4 study.